JP2010515081A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010515081A5 JP2010515081A5 JP2009544971A JP2009544971A JP2010515081A5 JP 2010515081 A5 JP2010515081 A5 JP 2010515081A5 JP 2009544971 A JP2009544971 A JP 2009544971A JP 2009544971 A JP2009544971 A JP 2009544971A JP 2010515081 A5 JP2010515081 A5 JP 2010515081A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- composition
- receptor agonist
- adenosine receptor
- partial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 36
- 239000003379 purinergic P1 receptor agonist Substances 0.000 claims 13
- 230000002107 myocardial Effects 0.000 claims 8
- LZPZPHGJDAGEJZ-AKAIJSEGSA-N Regadenoson Chemical compound C1=C(C(=O)NC)C=NN1C1=NC(N)=C(N=CN2[C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C2=N1 LZPZPHGJDAGEJZ-AKAIJSEGSA-N 0.000 claims 5
- 229960003614 regadenoson Drugs 0.000 claims 5
- 230000017531 blood circulation Effects 0.000 claims 4
- 230000004064 dysfunction Effects 0.000 claims 4
- 238000003384 imaging method Methods 0.000 claims 4
- 230000000261 vasodilator Effects 0.000 claims 4
- 239000003071 vasodilator agent Substances 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
Claims (20)
- ヒト患者において血管拡張薬誘発性心筋ストレスの灌流画像化の間に心筋機能不全を診断するための組成物であって、該組成物は、少なくとも1つの部分A2Aアデノシン受容体アゴニストを含み、該患者が最大下運動をしている間に該患者に投与され、そして少なくとも10μgの該部分A 2A アデノシン受容体アゴニストが投与されるような量で投与されるものであることを特徴とする、組成物。
- 前記組成物は、前記患者に約1000μg以下の前記部分A2Aアデノシン受容体アゴニストが投与されるように投与されるものであることを特徴とする、請求項1に記載の組成物。
- 前記組成物は、前記投与される部分A2Aアデノシン受容体アゴニストの量が約600μgを超えるように投与されるものであることを特徴とする、請求項1に記載の組成物。
- 前記組成物は、前記投与される部分A2Aアデノシン受容体アゴニストの量が約100μgを超えるように投与されるものであることを特徴とする、請求項1に記載の組成物。
- 前記組成物は、前記投与される部分A2Aアデノシン受容体アゴニストの量が約10μg〜約600μgの範囲にあるように投与されるものであることを特徴とする、請求項1に記載の組成物。
- 単一用量で投与されるものであることを特徴とする、請求項5に記載の組成物。
- 静脈内ボーラスによって投与されるものであることを特徴とする、請求項6に記載の組成物。
- 約10秒未満で投与されるものであることを特徴とする、請求項6に記載の組成物。
- 前記組成物は、前記投与される部分A2Aアデノシン受容体アゴニストの量が約500μgを超えるように投与されるものであることを特徴とする、請求項6に記載の組成物。
- 前記組成物は、前記部分A2Aアデノシン受容体アゴニストが約100μg〜約500μgの範囲の量で投与されるように投与されるものであることを特徴とする、請求項6に記載の組成物。
- 前記部分A2Aアデノシン受容体アゴニストが、CVT−3033、リガデノソンおよびそれらの組合せからなる群から選択される、請求項1に記載の組成物。
- ヒト患者において血管拡張薬誘発性心筋ストレスの灌流画像化の間に心筋機能不全を診断するための組み合わせ物であって、該組み合わせ物は、放射性核種および部分A2A受容体アゴニストを含み、該患者が最大下運動をしている間に投与されるものであり、該部分A 2A 受容体アゴニストは、約10μg〜約600μgの範囲の量で投与されるものであることを特徴とする、組み合わせ物。
- 前記部分A2Aアデノシン受容体アゴニストの前記投与が冠動脈血流の少なくとも2.5倍の増加を引き起こす、請求項12に記載の組み合わせ物。
- 冠動脈血流の前記少なくとも2.5倍の増加が、前記部分A2Aアデノシン受容体アゴニストの前記投与から約1分以内に達成される、請求項13に記載の組み合わせ物。
- 前記放射性核種および前記部分A2Aアデノシン受容体アゴニストが別々に投与されることを特徴とする、請求項12に記載の組み合わせ物。
- 前記放射性核種および前記部分A2Aアデノシン受容体アゴニストが同時に投与されることを特徴とする、請求項12に記載の組み合わせ物。
- 冠動脈血流の前記少なくとも2.5倍の増加の持続期間が約5分未満である、請求項13に記載の組み合わせ物。
- 冠動脈血流の前記少なくとも2.5倍の増加の持続期間が約3分未満である、請求項17に記載の組み合わせ物。
- ヒト患者において血管拡張薬誘発性心筋ストレスの灌流画像化の間に心筋機能不全を診断するための組成物であって、該組成物は、リガデノソンを含み、該患者が最大下運動をしている間に投与され、リガデノソンが約10〜約600μgの範囲の量で投与されるように単一の静脈内ボーラスによって投与されるものであることを特徴とする、組成物。
- ヒト患者において血管拡張薬誘発性心筋ストレスの灌流画像化の間に心筋機能不全を診断するための組成物であって、該組成物は、リガデノソンを含み、該患者が最大下運動をしている間に投与され、リガデノソンが約100〜約500μgの範囲の量で投与されるように単一の静脈内ボーラスによって投与されるものであることを特徴とする、組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87852907P | 2007-01-03 | 2007-01-03 | |
PCT/US2008/050117 WO2008086096A2 (en) | 2007-01-03 | 2008-01-03 | Myocardial perfusion imaging |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010515081A JP2010515081A (ja) | 2010-05-06 |
JP2010515081A5 true JP2010515081A5 (ja) | 2011-02-24 |
Family
ID=39485181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009544971A Pending JP2010515081A (ja) | 2007-01-03 | 2008-01-03 | 心筋灌流画像化 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080267861A1 (ja) |
EP (1) | EP2099360A2 (ja) |
JP (1) | JP2010515081A (ja) |
CA (1) | CA2673653A1 (ja) |
MX (1) | MX2009007071A (ja) |
WO (1) | WO2008086096A2 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
AU2001238665A1 (en) * | 2000-02-23 | 2001-09-03 | Cv Therapeutics, Inc. | Method of identifying partial agonists of the a2a receptor |
CN1671399A (zh) * | 2002-07-29 | 2005-09-21 | Cv医药有限公司 | 利用a2a受体激动剂的心肌灌注显像 |
US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
CA2583185A1 (en) * | 2004-10-20 | 2006-04-27 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists |
EP2581381A3 (en) * | 2006-02-03 | 2013-10-30 | Gilead Sciences, Inc. | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
JP2009541354A (ja) * | 2006-06-22 | 2009-11-26 | シーブイ・セラピューティクス・インコーポレイテッド | 虚血の治療におけるa2aアデノシン受容体アゴニストの使用 |
WO2008028140A1 (en) * | 2006-09-01 | 2008-03-06 | Cv Therapeutics, Inc. | Methods and compositions for increasing patient tolerability during myocardial imaging methods |
US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
CA2663361A1 (en) * | 2006-09-29 | 2008-04-10 | Cv Therapeutics, Inc. | Methods for myocardial imaging in patients having a history of pulmonary disease |
WO2010004365A1 (en) | 2008-07-10 | 2010-01-14 | Ecole Polytechnique Federale De Lausanne (Epfl) | Functional optical coherent imaging |
JP2012504147A (ja) * | 2008-09-29 | 2012-02-16 | ギリアード サイエンシーズ, インコーポレイテッド | 多検出器型コンピュータ断層撮影法において使用するための心拍数コントロール薬およびA−2−α受容体作動薬の組み合わせ |
US8880457B2 (en) * | 2010-11-05 | 2014-11-04 | Allegheny-Singer Research Institute | Method and system for recommending a decision based on combined entity modeling |
US9072490B2 (en) * | 2010-12-20 | 2015-07-07 | Toshiba Medical Systems Corporation | Image processing apparatus and image processing method |
EP2840957B1 (en) * | 2012-04-27 | 2024-01-03 | Stryker European Operations Limited | Optical coherent imaging medical device and method |
WO2017059302A1 (en) * | 2015-09-30 | 2017-04-06 | Cedars-Sinai Medical Center | Robust myocardial blood oxygen level dependent magnetic resonance imaging with long-acting coronary vasodilators |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4120947A (en) * | 1976-03-31 | 1978-10-17 | Cooper Laboratories, Inc. | Xanthine compounds and method of treating bronchospastic and allergic diseases |
US4089959A (en) * | 1976-03-31 | 1978-05-16 | Cooper Laboratories, Inc. | Long-acting xanthine bronchodilators and antiallergy agents |
SE7810946L (sv) * | 1978-10-20 | 1980-04-21 | Draco Ab | Metod att behandla kronisk obstruktiv luftvegssjukdom |
US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US4593095A (en) * | 1983-02-18 | 1986-06-03 | The Johns Hopkins University | Xanthine derivatives |
US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US4696932A (en) * | 1984-10-26 | 1987-09-29 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically-active xanthine derivatives |
JPS6299395A (ja) * | 1985-10-25 | 1987-05-08 | Yamasa Shoyu Co Ltd | 2−アルキニルアデノシンおよび抗高血圧剤 |
US4968697A (en) * | 1987-02-04 | 1990-11-06 | Ciba-Geigy Corporation | 2-substituted adenosine 5'-carboxamides as antihypertensive agents |
US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US4902514A (en) * | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
US5070877A (en) * | 1988-08-11 | 1991-12-10 | Medco Research, Inc. | Novel method of myocardial imaging |
DE3831430A1 (de) * | 1988-09-15 | 1990-03-22 | Bayer Ag | Substituierte 4-heterocyclyloximino-pyrazolin-5-one, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
KR0137786B1 (ko) * | 1988-11-15 | 1998-05-15 | 하마구찌 미찌오 | 심장 또는 뇌의 허혈성 질환의 치료, 예방제 |
DE69022176T2 (de) * | 1989-06-20 | 1996-02-15 | Toa Eiyo Ltd., Tokio/Tokyo | Zwischenverbindung für 2-alkynyladenosinherstellung, herstellung dieser zwischenverbindung, herstellung von 2-alkynyladenosin aus diesem zwischenprodukt sowie stabiles 2-alkynyladenosinderivat. |
US5032252A (en) * | 1990-04-27 | 1991-07-16 | Mobil Oil Corporation | Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator |
DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
US5189027A (en) * | 1990-11-30 | 1993-02-23 | Yamasa Shoyu Kabushiki Kaisha | 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases |
JP2740362B2 (ja) * | 1991-02-12 | 1998-04-15 | ヤマサ醤油株式会社 | 安定な固体状2‐オクチニルアデノシンおよびその製造法 |
US5516894A (en) * | 1992-03-11 | 1996-05-14 | The General Hospital Corporation | A2b -adenosine receptors |
IT1254915B (it) * | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
US5705491A (en) * | 1992-10-27 | 1998-01-06 | Nippon Zoki Pharmaceutical Co., Ltd. | Adenosine deaminase inhibitor |
CA2112031A1 (en) * | 1992-12-24 | 1994-06-25 | Fumio Suzuki | Xanthine derivatives |
US5477857A (en) * | 1993-09-10 | 1995-12-26 | Discovery Therapeutics, Inc. | Diagnostic uses of hydrazinoadenosines |
DE69526822T2 (de) * | 1994-02-23 | 2003-01-23 | Kyowa Hakko Kogyo Kk | Xanthin-derivate |
US5704491A (en) * | 1995-07-21 | 1998-01-06 | Cummins-Allison Corp. | Method and apparatus for discriminating and counting documents |
US5646156A (en) * | 1994-04-25 | 1997-07-08 | Merck & Co., Inc. | Inhibition of eosinophil activation through A3 adenosine receptor antagonism |
US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
US6514949B1 (en) * | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
US6448235B1 (en) * | 1994-07-11 | 2002-09-10 | University Of Virginia Patent Foundation | Method for treating restenosis with A2A adenosine receptor agonists |
US5854081A (en) * | 1996-06-20 | 1998-12-29 | The University Of Patent Foundation | Stable expression of human A2B adenosine receptors, and assays employing the same |
US5780481A (en) * | 1996-08-08 | 1998-07-14 | Merck & Co., Inc. | Method for inhibiting activation of the human A3 adenosine receptor to treat asthma |
US5776960A (en) * | 1996-10-16 | 1998-07-07 | Buckman Laboratories International, Inc. | Synergistic antimicrobial compositions containing an ionene polymer and a pyrithione salt and methods of using the same |
US5770716A (en) * | 1997-04-10 | 1998-06-23 | The Perkin-Elmer Corporation | Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same |
US6026317A (en) * | 1998-02-06 | 2000-02-15 | Baylor College Of Medicine | Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists |
US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
US6322771B1 (en) * | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
US6403567B1 (en) * | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
US6368573B1 (en) * | 1999-11-15 | 2002-04-09 | King Pharmaceuticals Research And Development, Inc. | Diagnostic uses of 2-substituted adenosine carboxamides |
US6605597B1 (en) * | 1999-12-03 | 2003-08-12 | Cv Therapeutics, Inc. | Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives |
US6294522B1 (en) * | 1999-12-03 | 2001-09-25 | Cv Therapeutics, Inc. | N6 heterocyclic 8-modified adenosine derivatives |
US6552023B2 (en) * | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
US6677336B2 (en) * | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
AU2001238665A1 (en) * | 2000-02-23 | 2001-09-03 | Cv Therapeutics, Inc. | Method of identifying partial agonists of the a2a receptor |
US6387913B1 (en) * | 2000-12-07 | 2002-05-14 | S. Jamal Mustafa | Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists |
US6670334B2 (en) * | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
US6995148B2 (en) * | 2001-04-05 | 2006-02-07 | University Of Pittsburgh | Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy |
US6599283B1 (en) * | 2001-05-04 | 2003-07-29 | Cv Therapeutics, Inc. | Method of preventing reperfusion injury |
US6919804B1 (en) * | 2001-05-08 | 2005-07-19 | Vultron Incorporated | Passenger detection system for vehicles |
ES2340664T3 (es) * | 2001-05-14 | 2010-06-08 | Novartis Ag | Derivados de sulfonamidas. |
US20030235555A1 (en) * | 2002-04-05 | 2003-12-25 | David Shealey | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
US7125993B2 (en) * | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
EP1444233B1 (en) * | 2001-11-09 | 2011-08-17 | Gilead Palo Alto, Inc. | A2b adenosine receptor antagonists |
US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
CN1671399A (zh) * | 2002-07-29 | 2005-09-21 | Cv医药有限公司 | 利用a2a受体激动剂的心肌灌注显像 |
CA2691611A1 (en) * | 2004-01-27 | 2005-09-09 | Gilead Palo Alto, Inc. | Myocardial perfusion imaging using adenosine receptor agonists |
WO2006044610A1 (en) * | 2004-10-15 | 2006-04-27 | Cv Therapeutics, Inc | Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists |
CA2583185A1 (en) * | 2004-10-20 | 2006-04-27 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists |
AU2006204716A1 (en) * | 2005-01-12 | 2006-07-20 | King Pharmaceuticals Reserch & Development, Inc. | Method of detecting myocardial dysfunction in patients having a history of asthma or bronchospasm |
EP2581381A3 (en) * | 2006-02-03 | 2013-10-30 | Gilead Sciences, Inc. | Process for preparing an A2A-adenosine receptor agonist and its polymorphs |
JP2009541354A (ja) * | 2006-06-22 | 2009-11-26 | シーブイ・セラピューティクス・インコーポレイテッド | 虚血の治療におけるa2aアデノシン受容体アゴニストの使用 |
WO2008028140A1 (en) * | 2006-09-01 | 2008-03-06 | Cv Therapeutics, Inc. | Methods and compositions for increasing patient tolerability during myocardial imaging methods |
US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
CA2663361A1 (en) * | 2006-09-29 | 2008-04-10 | Cv Therapeutics, Inc. | Methods for myocardial imaging in patients having a history of pulmonary disease |
-
2008
- 2008-01-03 WO PCT/US2008/050117 patent/WO2008086096A2/en active Application Filing
- 2008-01-03 EP EP08727357A patent/EP2099360A2/en not_active Withdrawn
- 2008-01-03 US US11/969,047 patent/US20080267861A1/en not_active Abandoned
- 2008-01-03 MX MX2009007071A patent/MX2009007071A/es not_active Application Discontinuation
- 2008-01-03 JP JP2009544971A patent/JP2010515081A/ja active Pending
- 2008-01-03 CA CA002673653A patent/CA2673653A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010515081A5 (ja) | ||
JP2010502649A5 (ja) | ||
JP2011502101A5 (ja) | ||
RU2009106862A (ru) | Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда | |
WO2006044856A3 (en) | Use of a2a adenosine receptor agonists | |
JP2005538190A5 (ja) | ||
AU2017328999B2 (en) | Combination of FXR agonists | |
CA2492855A1 (en) | Myocardial perfusion imaging using a2a receptor agonists | |
AU2020203316B2 (en) | Novel regimes of FXR agonists | |
CN101068549A (zh) | 与5-fu和5-fu前药组合施用dpd抑制剂的方法 | |
WO2009143101A3 (en) | Gastrin releasing peptide compounds | |
Okamura et al. | Imaging of activity of multidrug resistance–associated protein 1 in the lungs | |
US20150018299A1 (en) | Treatment of liver conditions | |
Cerqueira | Advances in pharmacologic agents in imaging: new A2A receptor agonists | |
CA3005961C (en) | An a3 adenosine receptor ligand for use in treating ectopic fat accumulation | |
Ross et al. | Acute blockade by endothelin-1 of haemodynamic insulin action in rats | |
Kiss et al. | Renin-Angiotensin-Aldosterone Signaling Inhibitors-Losartan, Enalapril, and Cardosten-Prevent Infarction-induced Heart Failure Development in Rats. | |
Corboz et al. | Assessment of inhaled treprostinil palmitil, inhaled and intravenous treprostinil, and oral selexipag in a sugen/hypoxia rat model of pulmonary arterial hypertension | |
Nakamura et al. | Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension | |
Pelleg et al. | The first second-generation adenosine drug enters the US market | |
Glover | The vasodilatory and cardioprotective properties of A2A adenosine receptor agonists | |
Thackeray | Examination of altered sympathetic nervous function in obesity and diabetes mellitus using [¹¹C] meta-hydroxyephedrine. | |
Seneca et al. | Imaging endogenous dopamine occupancy of the D2 receptor in rat brain with [11C] MNPA | |
Thackeray | Examination of altered sympathetic nervous function in obesity and diabetes mellitus using [carbon-11] meta-hydroxyephedrine | |
Clapp | Interactions of Prostacyclin and Endothelin. |